- The company is moving towards a new era of sustainable growth focused on the value of people from a triple perspective: patients, customers and the TAAV team itself.
- To accompany the new brand strategy and positioning, the enzyme DNA manufactured by the company has been renamed neDNA™.
TAAV Biomanufacturing Solutions S.L.U., a wholly owned subsidiary of Asklepios Biopharmaceuticals (AskBio) and Bayer AG, today unveils a new brand that supports the company’s transformation and purpose. The strategy aims to become the DNA manufacturing partner of choice for companies developing recombinant adeno-associated virus (rAAV) technologies and to become a key part of the gene therapy industry.
“The creation of this new brand for TAAV allows us to visually respond to our desire to express the transformation and leadership that our company is evolving towards,” says Dolores Baksh, CEO of TAAV. “Thanks to this rebranding, TAAV is now strengthened by an image that captures our leadership, potential and vision for the future”.
TAAV has carved a niche in the global gene therapy market through the enzymatic DNA it manufactures and offers to customers with rAAV projects at various stages from research to pre-clinical and clinical development. This story includes the first approval of enzyme material manufactured by TAAV for use in a clinical trial, which was approved in September 2022 by the French National Agency for the Safety of Medicines and Medical Devices (ANSM) for a Phase 1/Phase 2 study.
This progress is an example of the company’s ability to adapt to new challenges and demands for alternatives to plasmid DNA production for clinical use. With key new collaborations and a broader presence, TAAV’s rebranding runs through the backbone of its offering with a new brand name for the enzymatic DNA it manufactures, now known as neDNA™.
A new modern and innovative visual identity
The new design introduced stems from the company’s essence of presenting itself as a key partner in the gene therapy industry, and aligns with the company’s forward-looking strategy of innovation and customer support. This combination of essence and innovation is reflected in the logo, the identity and the new website as well as in the rest of the materials presented.
TAAV
Gene therapy, gene therapy, biotechnology, biotechnology, biomanufacturing, enzymatic, synthetic, enzymatic, synthetic, DNA, DNA, synthetic DNA, enzymatic DNA, alternative to plasmid, AAV, rAAV, adeno-associated viruses, partner, CDMO, AAV manufacturing. TAAV Biomanufacturing Solutions, SLU (TAAV), a wholly owned subsidiary of Asklepios Biopharmaceuticals (AskBio) and Bayer AG, manufactures enzymatic DNA for the production of recombinant adeno-associated viruses (rAAVs)…
